Given the large replication of the findings that IL11 underlies both common and rare forms of lung fibrosis through combined effects on lung epithelial and stromal cells and replicated therapeutic effects of anti-IL11 interventions, it is not surprising that the first clinical trials of anti-Il11 therapies are focused mainly on lung fibrosis, as discussed below. This evidence concerns the gene IL11 and pulmonary fibrosis.